Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000170

Drug Information
NameMLN8237
CompanyTakeda & Millennium
IndicationAcute myelogenous leukemia, High-risk myelodysplastic syndrome and Ovarian cancer
[ICD9: 140-229, 183, 205.0, 208.9, 238.7   ICD10: C00-C96, C56, C91-C95, C92.0, D46]
Phase II    
Advanced solid tumours and haematological malignancies
[ICD9: 140-229   ICD10: C00-C96]
Phase I    
Paediatric solid tumours or ALL
[ICD9: 140-199   ICD10: C00-C75, C7A, C7B]
Phase I/II    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17
(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)
37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)
InChIKeyZLHFILGSQDJULK-UHFFFAOYSA-N
Canonical SMILESCOC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)
O)OC    
Therapeutic ClassAntineoplastic Agents
PubChem Compound IDCID 24771867.
ClinicalTrials.govNCT00500903;
NCT00739427;
NCT00830518;
TargetAurora A kinaseInhibitor[1]
Ref 1Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. Journal of Clinical Oncology, 2009:8553 To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543